CPIX · Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. (CPIX) announced a strategic transaction to sell its portfolio of six FDA-approved branded pharmaceuticals to an affiliate of Apotex Inc., the largest Canadian pharmaceutical company, for $100 million in cash. The deal, structured as an asset purchase, is intended to unlock shareholder value and allow Cumberland to focus on its pipeline of ifetroban product candidates targeting Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. The transaction has been unanimously approved by Cumberland's board and is subject to approval by a majority of outstanding shares. Stockholders representing approximately 41% of outstanding shares have entered into voting agreements to support the deal. Key terms include a $4 million termination fee payable by either party under specified conditions, a mutual non-solicitation of employees for 18 months, and a four-year non-compete for Cumberland. Additionally, Apotex may owe a milestone payment if it secures a U.S. government contract for Vibativ within two years. The closing is expected by August 20, 2026. The company's financial advisor, VelocityHealth Securities, delivered a fairness opinion. This transaction represents a significant shift for Cumberland, transitioning from a commercial-stage specialty pharma to a development-stage biotech focused on orphan drug candidates.